0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Clinical Case Conference   |    
Schizophrenia Complicated by Chronic Hepatitis C Virus and Hepatic Encephalopathy
Mark Viron, M.D.; Adam Philip Stern, M.D.; Matcheri S. Keshavan, M.D.
Am J Psychiatry 2014;171:25-31. doi:10.1176/appi.ajp.2013.13020238
View Author and Article Information

Dr. Viron has served as a consultant for Optimal Medicine. The other authors report no financial relationships with commercial interests.

From Massachusetts Mental Health Center, Boston; the Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston; Harvard Medical School, Boston; Harvard Longwood Psychiatry Residency Training Program, Boston.

Address correspondence to Dr. Viron (mark.viron@state.ma.us).

Copyright © 2014 by the American Psychiatric Association

Received February 19, 2013; Revised March 31, 2013; Accepted April 22, 2013.

Extract

Figures in this Article

First Page Preview

View Large
/>
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 1. Interactions Between Schizophrenia and Liver Disease
+

References

Bell  BP;  Manos  MM;  Zaman  A;  Terrault  N;  Thomas  A;  Navarro  VJ;  Dhotre  KB;  Murphy  RC;  Van Ness  GR;  Stabach  N;  Robert  ME;  Bower  WA;  Bialek  SR;  Sofair  AN:  The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance.  Am J Gastroenterol 2008; 103:2727–2736
[CrossRef] | [PubMed]
 
Goldberg  RW;  Seth  P:  Hepatitis C services and individuals with serious mental illness.  Community Ment Health J 2008; 44:381–384
[CrossRef] | [PubMed]
 
Osher  FC;  Goldberg  RW;  McNary  SW;  Swartz  MS;  Essock  SM;  Butterfield  MI;  Rosenberg  SD; Five-Site Health and Risk Study Research Committee:  Substance abuse and the transmission of hepatitis C among persons with severe mental illness.  Psychiatr Serv 2003; 54:842–847
[CrossRef] | [PubMed]
 
Regier  DA;  Farmer  ME;  Rae  DS;  Locke  BZ;  Keith  SJ;  Judd  LL;  Goodwin  FK:  Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study.  JAMA 1990; 264:2511–2518
[CrossRef] | [PubMed]
 
Carey  MP;  Carey  KB;  Kalichman  SC:  Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses.  Clin Psychol Rev 1997; 17:271–291
[CrossRef] | [PubMed]
 
Chen  SL;  Morgan  TR:  The natural history of hepatitis C virus (HCV) infection.  Int J Med Sci 2006; 3:47–52
[CrossRef] | [PubMed]
 
Hu  KQ;  Tong  MJ:  The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States.  Hepatology 1999; 29:1311–1316
[CrossRef] | [PubMed]
 
Safdar  K;  Schiff  ER:  Alcohol and hepatitis C.  Semin Liver Dis 2004; 24:305–315
[CrossRef] | [PubMed]
 
Davis  GL;  Alter  MJ;  El-Serag  H;  Poynard  T;  Jennings  LW:  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.  Gastroenterology 2010; 138:513–521, e1–e6
[CrossRef] | [PubMed]
 
Deuffic-Burban  S;  Poynard  T;  Sulkowski  MS;  Wong  JB:  Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States.  J Viral Hepat 2007; 14:107–115
[CrossRef] | [PubMed]
 
Yee  HS;  Chang  MF;  Pocha  C;  Lim  J;  Ross  D;  Morgan  TR;  Monto  A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office:  Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.  Am J Gastroenterol 2012; 107:669–689, quiz 690
[CrossRef] | [PubMed]
 
McGowan  CE;  Fried  MW:  Barriers to hepatitis C treatment.  Liver Int 2012; 32(suppl 1):151–156
[CrossRef] | [PubMed]
 
Evon  DM;  Simpson  K;  Kixmiller  S;  Galanko  J;  Dougherty  K;  Golin  C;  Fried  MW:  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.  Am J Gastroenterol 2011; 106:1777–1786
[CrossRef] | [PubMed]
 
Freudenreich  O;  Gandhi  RT;  Walsh  JP;  Henderson  DC;  Goff  DC:  Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort.  Psychosomatics 2007; 48:405–411
[CrossRef] | [PubMed]
 
Smith  BD;  Morgan  RL;  Beckett  GA;  Falck-Ytter  Y;  Holtzman  D;  Ward  JW:  Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention.  Ann Intern Med 2012; 157:817–822
[CrossRef] | [PubMed]
 
Rosenberg  S;  Brunette  M;  Oxman  T;  Marsh  B;  Dietrich  A;  Mueser  K;  Drake  R;  Torrey  W;  Vidaver  R:  The STIRR model of best practices for blood-borne diseases among clients with serious mental illness.  Psychiatr Serv 2004; 55:660–664
[CrossRef] | [PubMed]
 
Huckans  M;  Mitchell  A;  Ruimy  S;  Loftis  J;  Hauser  P:  Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.  Schizophr Bull 2010; 36:165–172
[CrossRef] | [PubMed]
 
Alter  HJ;  Liang  TJ:  Hepatitis C: the end of the beginning and possibly the beginning of the end.  Ann Intern Med 2012; 156:317–318
[CrossRef] | [PubMed]
 
Prakash  R;  Mullen  KD:  Mechanisms, diagnosis, and management of hepatic encephalopathy.  Nat Rev Gastroenterol Hepatol 2010; 7:515–525
[CrossRef] | [PubMed]
 
Wakim-Fleming  J:  Hepatic encephalopathy: suspect it early in patients with cirrhosis.  Cleve Clin J Med 2011; 78:597–605
[CrossRef] | [PubMed]
 
Cummings  JL:  Organic delusions: phenomenology, anatomical correlations, and review.  Br J Psychiatry 1985; 146:184–197
[CrossRef] | [PubMed]
 
Munoz  SJ:  Hepatic encephalopathy.  Med Clin North Am 2008; 92:795–812
[CrossRef] | [PubMed]
 
Montgomery  JY;  Bajaj  JS:  Advances in the evaluation and management of minimal hepatic encephalopathy.  Curr Gastroenterol Rep 2011; 13:26–33
[CrossRef] | [PubMed]
 
Heinrichs  RW;  Zakzanis  KK:  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.  Neuropsychology 1998; 12:426–445
[CrossRef] | [PubMed]
 
Gleason  OC:  Delirium.  Am Fam Physician 2003; 67:1027–1034
[PubMed]
 
Keshavan  MS;  Kaneko  Y:  Secondary psychoses: an update.  World Psychiatry 2013; 12:4–15
[CrossRef] | [PubMed]
 
Crone  CC;  Gabriel  GM;  DiMartini  A:  An overview of psychiatric issues in liver disease for the consultation-liaison psychiatrist.  Psychosomatics 2006; 47:188–205
[CrossRef] | [PubMed]
 
Ong  JP;  Aggarwal  A;  Krieger  D;  Easley  KA;  Karafa  MT;  Van Lente  F;  Arroliga  AC;  Mullen  KD:  Correlation between ammonia levels and the severity of hepatic encephalopathy.  Am J Med 2003; 114:188–193
[CrossRef] | [PubMed]
 
Bass  NM;  Mullen  KD;  Sanyal  A;  Poordad  F;  Neff  G;  Leevy  CB;  Sigal  S;  Sheikh  MY;  Beavers  K;  Frederick  T;  Teperman  L;  Hillebrand  D;  Huang  S;  Merchant  K;  Shaw  A;  Bortey  E;  Forbes  WP:  Rifaximin treatment in hepatic encephalopathy.  N Engl J Med 2010; 362:1071–1081
[CrossRef] | [PubMed]
 
Taylor  D;  Paton  C;  Kapur  S:  The Maudsley Prescribing Guidelines in Psychiatry , 11th ed.  Chichester, UK,  John Wiley & Sons, 2012
 
Al Mutairi  F;  Dwivedi  G;  Al Ameel  T:  Fulminant hepatic failure in association with quetiapine: a case report.  J Med Case Reports 2012; 6:418
[CrossRef]
 
Sheehan  JJ;  Sliwa  JK;  Amatniek  JC;  Grinspan  A;  Canuso  CM:  Atypical antipsychotic metabolism and excretion.  Curr Drug Metab 2010; 11:516–525
[CrossRef] | [PubMed]
 
McIlwain  ME;  Harrison  J;  Wheeler  AJ;  Russell  BR:  Pharmacotherapy for treatment-resistant schizophrenia.  Neuropsychiatr Dis Treat 2011; 7:135–149
[PubMed]
 
Liukkonen  T;  Sorjonen  M;  Jokelainen  J;  Timonen  M:  Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment.  Psychosomatics 2008; 49:86–88
[CrossRef] | [PubMed]
 
Green  AI;  Drake  RE;  Brunette  MF;  Noordsy  DL:  Schizophrenia and co-occurring substance use disorder.  Am J Psychiatry 2007; 164:402–408
[CrossRef] | [PubMed]
 
da Silva  VC;  Bittencourt  PL;  Pinho  S;  Cavalcanti  AR;  Zollinger  CC:  Delayed-onset hepatic encephalopathy induced by zolpidem: a case report.  Clinics (Sao Paulo) 2008; 63:565–566
[CrossRef] | [PubMed]
 
Tek  C;  Srihari  V;  Tek  E:  Successful acamprosate treatment of alcohol dependence in schizophrenia.  Schizophr Res 2008; 106:373
[CrossRef] | [PubMed]
 
Ralevski  E;  O’Brien  E;  Jane  JS;  Dwan  R;  Dean  E;  Edens  E;  Arnaout  B;  Keegan  K;  Drew  S;  Petrakis  I:  Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence.  J Dual Diagn 2011; 7:64–73
[CrossRef]
 
Addolorato  G;  Mirijello  A;  Leggio  L;  Ferrulli  A;  Landolfi  R:  Management of alcohol dependence in patients with liver disease.  CNS Drugs 2013; 27:287–299
[CrossRef] | [PubMed]
 
Huguelet  P;  Morand-Collomb  S:  Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse.  Pharmacol Res 2005; 52:392–394
[CrossRef] | [PubMed]
 
Agabio  R;  Marras  P;  Addolorato  G;  Carpiniello  B;  Gessa  GL:  Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report.  J Clin Psychopharmacol 2007; 27:319–320
[CrossRef] | [PubMed]
 
Addolorato  G;  Leggio  L;  Ferrulli  A;  Cardone  S;  Vonghia  L;  Mirijello  A;  Abenavoli  L;  D’Angelo  C;  Caputo  F;  Zambon  A;  Haber  PS;  Gasbarrini  G:  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.  Lancet 2007; 370:1915–1922
[CrossRef] | [PubMed]
 
Viron  MJ;  Stern  TA:  The impact of serious mental illness on health and healthcare.  Psychosomatics 2010; 51:458–465
[PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 41.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 41.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 41.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 41.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 41.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles